Merrimack Pharmaceuticals, Inc.
MACK
MACK was delisted on the 17th of May, 2024.
12 hedge funds and large institutions have $5.32M invested in Merrimack Pharmaceuticals, Inc. in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 62 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
83% less funds holding
Funds holding: 70 → 12 (-58)
94% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 62
96% less capital invested
Capital invested by funds: $137M → $5.32M (-$132M)
100% less funds holding in top 10
Funds holding in top 10: 3 → 0 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JC
JBF Capital
Aspen,
Colorado
|
+$588K |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$567K |
| 3 |
Goldman Sachs
New York
|
+$228K |
| 4 |
CSC
Caldwell Sutter Capital
Sausalito,
California
|
+$111K |
| 5 |
FFA
Farther Finance Advisors
San Francisco,
California
|
+$1.14K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WSL
Western Standard LLC
Los Angeles,
California
|
-$32.1M |
| 2 |
NM
Newtyn Management
New York
|
-$27.7M |
| 3 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$13.3M |
| 4 |
BlackRock
New York
|
-$10.7M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$9.17M |
MACK Hedge Fund Activity: Q2 2024 in Review
12 of the 6,925 institutional investors tracked by Wall St. Rank reported a position in Merrimack Pharmaceuticals, Inc. (MACK) for Q2 2024, worth a combined $5.32M — down 96% from $137M a quarter earlier.
Sellers outnumbered buyers: 62 funds closed out of MACK and 4 opened new positions — a net loss of 58 holders — while 2 trimmed existing stakes and 2 added.
The largest buyer was JBF Capital, opening a new position worth an estimated $588K. The largest seller was Western Standard LLC, exiting entirely with an estimated $32.1M sold.
- 12 institutional investors held Merrimack Pharmaceuticals, Inc. (MACK) as of Q2 2024, down from 70 in Q1 2024.
- Funds reported $5.32M of Merrimack Pharmaceuticals, Inc. stock for Q2 2024, down 96% quarter-over-quarter.
- 4 funds opened new Merrimack Pharmaceuticals, Inc. positions in Q2 2024 and 62 closed out, a net change of -58 holders.
- The largest Merrimack Pharmaceuticals, Inc. buyer in Q2 2024 was JBF Capital, an estimated $588K added.
- The largest Merrimack Pharmaceuticals, Inc. seller in Q2 2024 was Western Standard LLC, an estimated $32.1M sold.
Based on aggregated 13F filings for Q2 2024.